Aduhelm's Journey To Accelerated Approval: Finding Buried Treasure In Uncharted Waters

The Alzheimer’s drug’s regulatory voyage to accelerated approval was circuitous – a destination briefly visited but one that reappeared on the horizon only as time ticked down on the application’s user fee goal date.